Maximus (MMS) Q3 2025 earnings review
Record Earnings and Third Guidance Raise Mask Temporary Cash Flow Crisis
Maximus delivered a stellar Q3, with Adjusted EPS of $2.16 beating expectations and driving a third consecutive raise to FY25 guidance. The outperformance was fueled by the U.S. Federal Services segment, where elevated clinical volumes drove revenue up 11% and pushed segment margins to an exceptional 18.1%. However, this strong P&L performance was overshadowed by a severe, albeit temporary, cash flow issue. A net outflow of $198M in free cash flow was caused by payment delays on two large programs, pushing Days Sales Outstanding (DSO) to a concerning 96 days. Management provided reassurance that collections have since normalized in July. The initial outlook for FY26 is cautious, forecasting revenue to be roughly flat with FY25.
🐂 Bull Case
The U.S. Federal segment continues to be the primary growth engine, delivering 11.4% organic growth and an exceptionally strong 18.1% operating margin. This demonstrates strong execution and operating leverage on high-volume clinical programs.
For the third consecutive quarter, management raised full-year FY25 guidance. The midpoint for Adjusted EPS was increased by $1.00 to $7.45, implying impressive 22% YoY growth and signaling strong confidence in underlying business momentum.
The 'One Big Beautiful Bill Act' is expected to create meaningful new opportunities in Medicaid (work requirements, semi-annual eligibility checks) and SNAP, positioning the company for a potential growth re-acceleration in FY27.
🐻 Bear Case
A negative FCF of nearly $200M and a DSO spike to 96 days highlight significant working capital risk. While management claims the issue is resolved, it reveals a vulnerability to payment timing on large contracts.
The preliminary FY26 forecast for revenue to be 'roughly in line' with FY25 implies a sharp deceleration from the current ~4% organic growth rate and suggests the elevated volumes driving recent beats are not sustainable.
The trailing-twelve-month book-to-bill ratio remains low at 0.8x. While management attributes this to the timing of large contract rebids, it still points to a potential gap in replacing burned revenue over the medium term.
⚖️ Verdict: 🟢
Bullish. The operational outperformance and magnitude of the earnings guidance raise are too significant to ignore. The Federal segment is executing flawlessly, and future legislative tailwinds provide a clear path for medium-term growth. While the Q3 cash flow was a major red flag, management's specific and credible explanation of a timing issue that was resolved post-quarter end mitigates the concern. The cautious FY26 outlook is prudent but likely conservative.
Key Themes
Cash Flow Reverses Sharply on Collection Delays
The most significant red flag this quarter was the stark divergence between earnings and cash flow. While Net Income was a positive $106M, Operating Cash Flow was a negative $183M, driven by a massive spike in Accounts Receivable. Days Sales Outstanding (DSO) jumped to 96 days from 73 last quarter. Management attributed this to administrative delays in finalizing an extension on a large state contract and payment timing on a major federal program, stating over $500M was collected in July. This highlights a concentration risk and dependency on timely payments from large government clients.
U.S. Federal Segment Delivers Exceptional Profitability
The U.S. Federal Services segment was the standout performer, with revenue growing 11.4% to $761M. More impressively, the segment's operating margin reached a record 18.1%, up from 15.5% a year ago and well above the ~15% guided for the full year. This performance was driven by sustained elevated volumes in the clinical assessment portfolio and demonstrates significant operating leverage, as the company efficiently processed higher-than-expected workloads on its performance-based contracts.
FY26 Outlook Signals a Growth Slowdown
Management's early outlook for FY26 suggests a significant slowdown. The forecast for revenue to be 'roughly in line with or possibly just slightly below' the raised FY25 guidance implies a near-zero growth rate. This confirms that the elevated volumes driving FY25 outperformance, particularly in the Federal clinical business and from prior Medicaid activity, are not expected to recur at the same levels. While prudent, this sets a cautious tone for the year ahead and points to a deceleration from the mid-single-digit organic growth target.
Expansion into Defense Market Gains Traction
Maximus is showing tangible progress in its strategy to expand into the defense sector. The company announced a new $77 million contract with the U.S. Air Force for cybersecurity and cloud services. This win is supported by the recent achievement of CMMC Level 2 certification, a critical requirement for DoD contractors. This establishes a new growth vector for the company, moving beyond its traditional civilian and health agency focus.
Legislative Changes Create Future State-Level Opportunities
The 'One Big Beautiful Bill Act' is set to create new addressable markets, primarily within the U.S. Services segment. New requirements, such as twice-yearly Medicaid eligibility redeterminations for the expansion population and codified work requirements, will necessitate state action by late 2026. Management views this as a significant tailwind for FY27 and beyond, as states will likely need partners like Maximus to implement these complex operational changes.
U.S. Services Segment Normalizing Post-Unwinding
As expected, the U.S. Services segment revenue declined 6.9% YoY to $440M. This was against a tough comparison from the prior year, which included a significant temporary boost from the Medicaid unwinding exercise. The segment's operating margin of 10.2% is a return to a more normalized level, compared to 13.0% in the inflated prior-year period. The full-year margin guidance for the segment remains ~10.5%.
Other KPIs
Accelerating. The margin reached a record 14.7%, significantly above the high end of the company's 10-13% target range. This compares to 13.7% in Q2, 11.2% in Q1, and 13.1% in the prior year period. Management attributes this to strong operating leverage on higher-than-anticipated volumes, a result of prior investments in technology and workflow optimization.
The total sales pipeline remains robust at $44.7B, of which 63% represents new work opportunities. However, the trailing-twelve-month book-to-bill ratio of 0.8x indicates that contract awards are not keeping pace with revenue burn, a metric to monitor despite management's explanation of it being a timing issue related to large rebids.
Guidance
Accelerating. The midpoint of the new range ($7.45) represents a significant increase from the prior guidance of $6.30 - $6.60. This implies a powerful 22% YoY growth compared to FY24's $6.11, driven by strong operational performance and share buybacks.
Stable. The raised guidance implies full-year organic growth of approximately 4%, a deceleration from FY24's 8.8% but an improvement from the ~2% implied by the prior guidance range. The increase is driven by the sustained strength in the U.S. Federal segment.
Stable. Despite the massive negative FCF in Q3, management raised the full-year FCF guidance by $10M at the midpoint. This signals strong confidence that the collection issues are resolved and that Q4 will see a very strong cash inflow, bringing the full-year conversion rate back to a healthy level.
Decelerating. The initial view for FY26 revenue to be 'roughly in line' with FY25 points to a sharp slowdown from FY25's ~4% growth. Management expects the adjusted EBITDA margin to remain healthy, near the high end of the 10-13% target range, but the flat top-line forecast suggests the current tailwinds from elevated volumes will subside.